Pancreatic Cancer Research

ResearcherNihon UniversityActive in the last 2 years

Kei Saito

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2290-9373; OpenAlex author ID A5026632503. Sources: OpenAlex.

Their work

Papers
20 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
48
Papers, trials and grants by year

2014: 1 paper · 2015: 3 papers · 2016: none · 2017: 2 papers · 2018: 2 papers · 2019: 2 papers · 2020: 1 paper · 2021: 4 papers · 2022: 1 paper · 2023: 3 papers · 2024: none · 2025: 1 paper

Papers 20

  1. Impact of Statin Use on Survival in Patients With Unresectable Pancreatic cancer Receiving Gemcitabine Plus Nab-Paclitaxel: A Multicenter Retrospective Study. Co-author DOI 10.1097/mpa.0000000000002411↗
  2. Early skeletal muscle mass decline is a prognostic factor in patients receiving gemcitabine plus nab-paclitaxel for unresectable pancreatic cancer: a retrospec… First author DOI 10.1007/s00520-023-07659-w↗
  3. Clinical Practice Guidelines for Pancreatic Cancer 2022 from the Japan Pancreas Society: a synopsis. Co-author DOI 10.1007/s10147-023-02317-x↗
  4. Gemcitabine plus nab-paclitaxel for pancreatic cancer and interstitial lung disease: A nationwide longitudinal study. Co-author DOI 10.1111/cas.15910↗
  5. Synopsis of a clinical practice guideline for pancreatic ductal adenocarcinoma with peritoneal dissemination in Japan; Japan Peritoneal Malignancy Study Group. Co-author DOI 10.1002/jhbp.1085↗
  6. A phase I study of intraperitoneal paclitaxel combined with gemcitabine plus nab-paclitaxel for pancreatic cancer with peritoneal metastasis. Co-author DOI 10.1007/s10637-020-00982-7↗
  7. A retrospective comparative study of S-IROX and modified FOLFIRINOX for patients with advanced pancreatic cancer refractory to gemcitabine plus nab-paclitaxel. Co-author DOI 10.1007/s10637-020-01022-0↗
  8. Protein intake after the initiation of chemotherapy is an independent prognostic factor for overall survival in patients with unresectable pancreatic cancer: A… Co-author DOI 10.1016/j.clnu.2021.06.011↗
  9. A Prospective Multicenter Study of Partially Covered Metal Stents in Patients Receiving Neoadjuvant Chemotherapy for Resectable and Borderline Resectable Pancr… Co-author DOI 10.5009/gnl19302↗
  10. Screening Strategy of Pancreatic Cancer in Patients with Diabetes Mellitus. Co-author DOI 10.3390/diagnostics10080572↗
  11. A phase II trial of gemcitabine, S-1 and LV combination (GSL) therapy in patients with advanced pancreatic cancer. Co-author DOI 10.1007/s10637-018-0691-9↗
  12. Diagnostic yield of the plasma free amino acid index for pancreatic cancer in patients with diabetes mellitus. Co-author DOI 10.1016/j.pan.2019.07.002↗
  13. A phase II trial of gemcitabine, S-1 and LV combination (GSL) neoadjuvant chemotherapy for patients with borderline resectable and locally advanced pancreatic … Co-author DOI 10.1007/s12032-018-1158-8↗
  14. A Multicenter Open-Label Randomized Controlled Trial of Pancreatic Enzyme Replacement Therapy in Unresectable Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001079↗
  15. The Role of Pancreatic Enzyme Replacement Therapy in Unresectable Pancreatic Cancer: A Prospective Cohort Study. Co-author DOI 10.1097/mpa.0000000000000767↗
  16. Thromboembolisms in Advanced Pancreatic Cancer: A Retrospective Analysis of 475 Patients. Co-author DOI 10.1097/mpa.0000000000000889↗
  17. The inhibition of renin-angiotensin system in advanced pancreatic cancer: an exploratory analysis in 349 patients. Co-author DOI 10.1007/s00432-014-1873-2↗
  18. Pancreatic cancer with malignant ascites: clinical features and outcomes. Co-author DOI 10.1097/mpa.0000000000000290↗
  19. [IPMN and pancreatic cyst as high risk of pancreatic cancer]. Co-author DOI 10.11405/nisshoshi.112.1474↗
  20. A phase I trial of gemcitabine, S-1 and LV combination (GSL) therapy in advanced pancreatic cancer. Co-author DOI 10.1007/s00280-014-2563-0↗

Closest collaborators

The 25 strongest of 48 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yousuke Nakai · 19 shared papers, 2014–2025 · strength 1.76
  2. Hiroyuki Isayama · 15 shared papers, 2014–2025 · strength 1.18
  3. Naminatsu Takahara · 15 shared papers, 2014–2023 · strength 1.11
  4. Kazuhiko Koike · 15 shared papers, 2014–2021 · strength 1.10
  5. Tsuyoshi Hamada · 13 shared papers, 2014–2023 · strength 1.04
  6. Kazunaga Ishigaki · 12 shared papers, 2015–2023 · strength 1.00
  7. Suguru Mizuno · 13 shared papers, 2014–2021 · strength 0.84
  8. Hirofumi Kogure · 13 shared papers, 2014–2021 · strength 0.84
  9. Tomotaka Saito · 9 shared papers, 2015–2023 · strength 0.76
  10. Hideaki Ijichi · 9 shared papers, 2014–2021 · strength 0.59
  11. Mitsuhiro Fujishiro · 3 shared papers, 2023–2025 · strength 0.54
  12. Minoru Tada · 10 shared papers, 2014–2019 · strength 0.53
  13. Saburo Matsubara · 7 shared papers, 2015–2025 · strength 0.52
  14. Hiroki Oyama · 3 shared papers, 2020–2025 · strength 0.45
  15. Tsuyoshi Takeda · 5 shared papers, 2015–2025 · strength 0.44
  16. Dai Mohri · 6 shared papers, 2014–2025 · strength 0.41
  17. Yukari Suzuki · 3 shared papers, 2020–2023 · strength 0.35
  18. Takashi Sasaki · 2 shared papers, 2019–2025 · strength 0.27
  19. Ko Tomishima · 1 shared paper, 2025 · strength 0.20
  20. Makoto Ueno · 1 shared paper, 2025 · strength 0.20
  21. Hideo Yasunaga · 1 shared paper, 2023 · strength 0.18
  22. Kazumichi Kawakubo · 2 shared papers, 2015–2021 · strength 0.16
  23. Tatsunori Suzuki · 1 shared paper, 2023 · strength 0.16
  24. Takashi Sasaki · 4 shared papers, 2014–2015 · strength 0.15
  25. Koji Miyabayashi · 4 shared papers, 2014–2015 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.